Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @
Roche’s Wilserdly Joins Oral SERD Market, But Adjuvant Indication Still Pending
RRoche

Roche’s Wilserdly Joins Oral SERD Market, But Adjuvant Indication Still Pending

  • 2026-11-17

Scrip logo

Roche’s giredestrant was approved by the US FDA for the treatment of ESR1-mutated, ER+, HER2- breast cancer, joining three other oral SERDs on the market.

breast cancerRoche has a new drug approved for breast cancer (Shutterstock) Key TakeawaysRoche’s Wilserdly (giredestrant) is the fourth next-generation oral selective estrogen receptor degrader (SERD) to reach the market for ESR1-mutated, ER+, HER2- advanced or metastatic breast cancer after endocrine therapy.

 

Roche’s Wilserdly (giredestrant) was approved by the US Food and Drug Administration as the fourth next-generation oral selective estrogen receptor…

  • Tags:
  • ER+
  • HER2- breast cancer
  • oral SERD
  • Roche
  • Wilserdly
Switzerland
www.europesays.com